SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare - Quaterly Results

26 May 2025 Evaluate
The sales figure stood at Rs. 1261.54 millions for the March 2025 quarter. The mentioned figure indicates a growth of about 44.26% as compared to Rs. 874.52 millions during the year-ago period.The Net Loss for the quarter ended March 2025 is Rs. -51.53 millions as compared to Net Profit of Rs. 97.37 millions of corresponding quarter ended March 2024Operating Profit saw a handsome growth to 493.17 millions from 302.07 millions in the quarter ended March 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 1261.54 874.52 44.26 4773.42 3097.87 54.09 4773.42 3097.87 54.09
Other Income 140.84 232.47 -39.42 838.34 891.16 -5.93 838.34 891.16 -5.93
PBIDT 493.17 302.07 63.26 2084.35 1154.08 80.61 2084.35 1154.08 80.61
Interest 20.88 27.11 -22.98 66.04 172.57 -61.73 66.04 172.57 -61.73
PBDT 29.09 237.12 -87.73 1560.93 877.00 77.99 1560.93 877.00 77.99
Depreciation 123.38 122.87 0.42 488.56 496.11 -1.52 488.56 496.11 -1.52
PBT -94.29 114.25 -182.53 1072.37 380.89 181.54 1072.37 380.89 181.54
TAX -42.76 16.88 -353.32 374.35 111.52 235.68 374.35 111.52 235.68
Deferred Tax -59.39 -4.97 1094.97 -96.43 -1.35 7042.96 -96.43 -1.35 7042.96
PAT -51.53 97.37 -152.92 698.02 269.37 159.13 698.02 269.37 159.13
Equity 97.79 86.80 12.66 97.79 86.80 12.66 97.79 86.80 12.66
PBIDTM(%) 39.09 34.54 13.18 43.67 37.25 17.21 43.67 37.25 17.21

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×